FindTrial
Sign In

Role of platelet rich plasma in infertile females with thin endometrium

Intrauterine instillation of autologous platelet rich plasma in infertile females with thin endometrium undergoing intrauterine insemination

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042399
Enrollment
55
Registered
2022-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intrauterine instillation of autologous Platelet rich plasma: Intrauterine instillation of autologous Platelet rich plasma in infertile females with thin endometrium undergoing intraute

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Infertile female between 21-37 years with normal ovarian reserve (AMH:1.2-4 ng/ml;AFC:5-15) , patent both tubes and normal seminogram/ or mild male factor undergoing IUI for mild cervical factor and/ or unexplained infertility. 2. Persistent thin endometrial thickness =1 cycle in previous cycle even after conventional treatment with estradiol valearate. 3. HB >11 gm% and platelets >1.5 lakhs

Exclusion criteria

Exclusion criteria: 1. History of symptoms of platelet dysfunction such as easy bruisability, frequent nose-bleeds, heavy menstrual bleeding, bleeding gums or excessive bleeding during dental procedures. 2. Blood borne disease like Hepatitis B, Hepatitis C, Syphilis, HIV. 3. NSAIDs intake in 10 days before the procedure 4. Pt on anticoagulant therapy 5. Severe Male factor for infertility 6. Tubal factor for infertility 7. WHO class 1 and 3 ovulatory dysfunction 8. Mullerian abnormality 9. Ashermann Syndrome 10. Endometritis 11. Moderate /severe endometriosis 12. Active vaginal/cervix infection/pelvic inflammatory disease. 13. Any significant co-morbidity/ psychiatric disorder which compromise or interfere with consent giving/study participation/ follow up or interpretation of study.

Design outcomes

Primary

MeasureTime frame
1)Change in endometrium thickness. 2)change in endometrium vascularity Timepoint: 1)baseline,36-40 hours 2)baseline,36-40 hours—

Secondary

MeasureTime frame
1)positive pregnancy rate 2)clinical pregnancy rate Timepoint: End point:The study will be stopped on achieving positive pregnancy or completion of three cycles of autologous PRP intrauterine instillation(whichever is earlier)—

Countries

India

Contacts

Public Contactdr divya pandey

Vardhman Mahavir Medical College and Safdarjung Hospital

dr_devya1@yahoo.co.in8860198440

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026